Boai NKY Medical Holdings Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Junzheng Zhang

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5.1yrs
Participación del CEO	0.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Junzheng Zhang (48 yo)

5.1yrs

Permanencia

CN¥312,000

Compensación

Mr. Junzheng Zhang serves as Chairman of the Board and Chief Executive Offier at Boai NKY Medical Holdings Ltd. He served as Secretary of the Board at Boai NKY Medical Holdings Ltd. (formerly known as Boai...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Junzheng Zhang	Chairman of the Board & GM	5.1yrs	CN¥312.00k	0.20% CN¥ 12.3m
Donghu Wang	Director	no data	CN¥336.90k	9.09% CN¥ 570.8m
Hongbo Yang	Vice Chairman of the Board	5.1yrs	CN¥315.40k	0.22% CN¥ 13.5m
Wei Zhao	Non-Independent Director	5.1yrs	CN¥120.00k	0.0072% CN¥ 451.3k
Tong Zhou	Independent Director	5.1yrs	CN¥108.00k	sin datos
Yunxia Qu	Chairman of the Supervisory Board	5.1yrs	CN¥173.70k	sin datos
Chunping Li	Non-Employee Supervisor	5.1yrs	sin datos	sin datos
Dalong Ren	Vice Chairman of the Board	8.8yrs	CN¥259.30k	sin datos
Haifeng Liu	Supervisor	5.1yrs	sin datos	sin datos
Rui Zhao	Independent Director	2.7yrs	sin datos	sin datos
Yongjun Fang	Independent Director	2.7yrs	CN¥90.00k	sin datos
Tao Chang	Non-Employee Supervisor	1.6yrs	sin datos	0.0032% CN¥ 203.4k

5.1yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 300109 se considera experimentada (4.8 años de antigüedad promedio).

Boai NKY Medical Holdings Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Boai NKY Medical Holdings Ltd., Annual General Meeting, May 23, 2024

High number of new directors

High number of new and inexperienced directors

Recent updates

Boai NKY Medical Holdings Ltd. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 22%

Now 26% overvalued

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.29 in 2Q 2023)

Boai NKY Medical Holdings Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dividend increased to CN¥1.00

Boai NKY Medical Holdings Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 07 June 2024

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for the Year 2023

Boai NKY Medical Holdings Ltd., Annual General Meeting, May 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.39 in 1Q 2023)

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2023

Now 23% overvalued after recent price rise

Boai NKY Medical Holdings Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥1.63 (vs CN¥0.88 in FY 2022)

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Investor sentiment deteriorates as stock falls 20%

Boai NKY Medical Holdings Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.42 in 3Q 2022)

Boai NKY Medical Holdings Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.34 in 2Q 2022)

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 30, 2023

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for 2022

First quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.10 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.91 in FY 2021)

Investor sentiment deteriorated over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.046 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Gryningskust Holding AB acquired additional 14.0 % minority stake in NeoDynamics AB (publ) (OM:NEOD).

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai Nky Medical Holdings Ltd. Approves Cash Dividend

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Boai NKY Medical Holdings Ltd. (SZSE:300109) commences a Equity Buyback Plan under the authorization approved on December 21, 2021.

Third quarter 2021 earnings released: EPS CN¥0.046 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.067 (vs CN¥0.12 in 2Q 2020)

Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Shanghai Haitong Securities Assets Management Co.,Ltd. completed the acquisition of 3% stake in Boai NKY Medical Holdings Ltd. (SZSE:300109) from Wang Donghu.

Boai Nky Medical Holdings Ltd. Approves Final Cash Dividend for 2020

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.04 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥11.20

New 90-day low: CN¥11.89

Ningbo Tianlong Electronics Co., Ltd. (SHSE:603266) entered into a equity transfer agreement to acquire 4.1818% stake in Wuhan First Bioscience Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for CNY 14 million.

New 90-day low: CN¥13.80

New 90-day low: CN¥15.06

New 90-day low: CN¥16.55

Third quarter earnings released

Market bids up stock over the past week

New 90-day high: CN¥19.40

New 90-day high: CN¥19.24

Fang Huasheng and Ren Dalong acquired 18.99% stake in Boai NKY Pharmaceuticals Ltd. (SZSE:300109).

New 90-day high - CN¥18.63

Earnings released

Boai NKY Medical Holdings Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥18.55

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad